Clinical Trial Update: Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients [Phase 2]

View source ↗

Summary

This notice reports the completion of a Phase 2 study evaluating QLS-111 in patients with primary open-angle glaucoma and ocular hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• QLS-111 (QLS-111)

Snippet

Sponsor: Qlaris Bio, Inc. | Conditions: Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes | Phase 2 | Status: COMPLETED